CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCDNA
āļāļ·āđāļāļāļĢāļīāļĐāļąāļCareDx Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 17, 2014
āļāļĩāļāļĩāđāļHanna (John W)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ644
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJul 17
āļāļĩāđāļāļĒāļđāđ8000 Marina Blvd
āđāļĄāļ·āļāļBRISBANE
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ94005
āđāļāļĢāļĻāļąāļāļāđ14152872300
āđāļ§āđāļāđāļāļāđhttps://www.caredx.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCDNA
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 17, 2014
āļāļĩāļāļĩāđāļHanna (John W)
Dr. Peter Maag, Ph.D.
Independent Director
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Ms. Jessica Meng
Chief Commercial Officer
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Mr. Nathan Smith
Chief Financial Officer
Ms. Christine M. Cournoyer
Ms. Christine M. Cournoyer
Independent Director
Mr. Suresh Gunasekaran
Director
Mr. Jeffrey Adam Novack
General Counsel, Secretary
General Counsel, Secretary
Ms. Caroline Corner
Investor Relations
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Peter Maag, Ph.D.
Independent Director
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Ms. Jessica Meng
Chief Commercial Officer
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Mr. Nathan Smith
Chief Financial Officer
ARK Genomic Revolution ETF
ROBO Global Healthcare Technology & Innovation ETF
Global X Genomics & Biotechnology ETF
Franklin Genomic Advancements ETF
State Street SPDR S&P Biotech ETF
Direxion Daily S&P Biotech Bull 3X Shares
Fidelity Enhanced Small Cap ETF
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Principal U.S. Small-Cap ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ARK Genomic Revolution ETF
āļŠāļąāļāļŠāđāļ§āļ2.89%
ROBO Global Healthcare Technology & Innovation ETF
āļŠāļąāļāļŠāđāļ§āļ1.93%
Global X Genomics & Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.87%
Franklin Genomic Advancements ETF
āļŠāļąāļāļŠāđāļ§āļ0.72%
State Street SPDR S&P Biotech ETF
āļŠāļąāļāļŠāđāļ§āļ0.34%
Direxion Daily S&P Biotech Bull 3X Shares
āļŠāļąāļāļŠāđāļ§āļ0.21%
iShares Micro-Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.16%
Fidelity Enhanced Small Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.11%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.11%
Principal U.S. Small-Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.1%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ